81/163US=57 / Biol/Mol
Weinberg RA. p53 e apoptose: guardião e executor. In: ___. A biologia do câncer. Porto Alegre: Artmed, 2008. p. 307-56. ISBN 978-85-363-1348-1.

P53; APOPTOSE; PAPOVAVIRUS; MUTACAO DE P53; ALEDOS MUTANTES HERDADOS; CELULAS CANCEROSAS


82/163US=67 / Biol/Mol
Knights CD, Pestell RG. The cell cycle: therapeutic targeting of cell regulatory components and effector pathways in cancer. In: Kaufman HL, Wadler S, Antman K. Molecular targeting in oncology. New Jersey: Humana Press, 2008. p. 3-32. (Cancer Drug Discovery and Development) ISBN 978-1-58829-577-4.

CICLO CELULAR; SEGMENTACAO TERAPEUTICA; COMPONENTES CELULARES; VIAS REGULADORAS; CANCER; CICLINA DEPENDENTE DE QUINASE; INIBIDORES CDK; TERAPIA; ACETILACAO; P53; CICLINA D1; EGFR; HDAC; STI-571; FLAVOPIRIDOL; INIBIDOR CDK2


83/163US=58 / Câncer
Kuang J, Wang R. Mechanisms of G2 phase arrest in DNA damage-induced checkpoint response. In: Siddik ZH. Checkpoint controls and targets in cancer therapy. New Jersey: Humana Press, 2008. p. 37-51. (Cancer Drug Discovery and Development Series) ISBN 978-1-60761-177-6.

G2 CHECKPOINT; CDC25; PP2A; 14-3-3; 14-3-3O; P53; P21; GADD45


84/163US=58 / Câncer
Lee MH, Yeung SCJ, Yang HY. Interplay of 14-3-3 family of proteins with DNA damage-regulated molecules in checkpoint control. In: Siddik ZH. Checkpoint controls and targets in cancer therapy. New Jersey: Humana Press, 2008. p. 69-80. (Cancer Drug Discovery and Development Series) ISBN 978-1-60761-177-6.

FAMILIA DE PROTEINAS COM 14-3-3; DANOS AO DNA; RESPOSTA CHECKPOINT; 14-3-3; AKT; MDM2; P53; DANOS NO DNA


85/163US=58 / Câncer
Nakanishi M. Chromatin modifications and orchestration of checkpoint response in cancer. In: Siddik ZH. Checkpoint controls and targets in cancer therapy. New Jersey: Humana Press, 2008. p. 83-93. (Cancer Drug Discovery and Development Series) ISBN 978-1-60761-177-6.

MODIFICACOES DE CROMATINA; ORQUESTRACAO DE RESPOSTA; CONTROLE EM CANCER; CHK1; CHK2; P53; REPLICACAO DO DNA


86/163US=58 / Câncer
Kaina B, Roos WP, Christmann M. DNA damage response and the balance between cell survival and cell death. In: Siddik ZH. Checkpoint controls and targets in cancer therapy. New Jersey: Humana Press, 2008. p. 95-108. (Cancer Drug Discovery and Development Series) ISBN 978-1-60761-177-6.

DANOS NO DNA; SOBREVIVENCIA CELULAR; MORTE CELULAR; CHECKPOINTS; CICLO CELULAR; RESPOSTA A DANOS DO DNA; REPARACAO DO ADN; P53; APOPTOSE; RECEPTORES DE MORTE; FAS; CAIXA ELETRONICO; ATR; DROGAS ANTICANCER


87/163US=58 / Câncer
Post SM, Quinás-Cardama A, Lozano G. Regulation of p53 activity and associated checkpoint controls. In: Siddik ZH. Checkpoint controls and targets in cancer therapy. New Jersey: Humana Press, 2008. p. 171-88. (Cancer Drug Discovery and Development Series) ISBN 978-1-60761-177-6.

P53; MDM2; P19; TUMORIGENESE; CANCER; RAS; CICLO CELULAR; RB; CICLINA; CDK


88/163US=58 / Câncer
Eastman A. The importance of p53 signaling in the response of cells to checkpoint inhibitors. In: Siddik ZH. Checkpoint controls and targets in cancer therapy. New Jersey: Humana Press, 2008. p. 189-98. (Cancer Drug Discovery and Development Series) ISBN 978-1-60761-177-6.

DANOS NO DNA; PARADA DO CICLO CELULAR; P53; P21; CICLINA B; CHK1 INIBIDORES; UCN-01; INIBIDORES DA TOPOISOMERASE II; ANALOGOS DE NUCLEOSIDOS


89/163US=70 / Biol/Mol
Bunz F. Tumor suppressor genes. In: ___. Principles of cancer genetics. New York: Springer, 2008. p. 77-124. ISBN 978-1-4020-6783-9.

GENES SUPRESSORES DE TUMORES; FENOTIPO RECESSIVO; RETINOBLASTOMA; HIPOTESE DE KNUDSON; LOCALIZACAO CROMOSSOMICA DO GENE; INATIVACAO DO P53; SINDROME DE LI-FRAUMENI; SUSCETIBILIDADE; CANCER DE MAMA; BRCA1; BRCA2; CDKN2A; PTEN; SMAD4; NEUROFIBROMATOSE; NEOPLASIA ENDOCRINA MULTIPLA TIPO 1; SINDROMES DE CANCER EM CAMUNDONGOS


90/163US=70 / Biol/Mol
Bunz F. Cancer gene pathways. In: ___. Principles of cancer genetics. New York: Springer, 2008. p. 173-226. ISBN 978-1-4020-6783-9.

CANCER; GENE; VIAS; VIAS CELULARES; INTERACAO PROTEINA-PROTEINA; REACOES BIOQUIMICAS; FOSFORILACAO DE PROTEINAS; SINAIS DA SUPERFICIE CELULAR; TIROSINA-QUINASES PROTEICAS; VIA RAS; FOSFORILACAO DE LIPIDIOS; VIA PI3K/AKT; MORFOGENESE; VIA WNT/APC; HOMEOSTASE; ATIVACAO P53; MDM2; APOPTOSE; CICLO CELULAR


91/163US=80 / Biol/Mol
Lee K, Wang T, Rehman A, Wang Y, Daoud SS. Cell signaling proteomics: integration of genomics and proteomics in dissecting p53 signaling. In: Daoud SS. Cancer proteomics from bench to bedside. New Jersey: Humana press, 2008. p. 39-57. (Cancer Drug Discovery and Development) ISBN 978-1-59745-169-7.

FARMACOGENOMICA; PROTEOMICA; P53; S100A4; RB18A; CANCER DO COLON


92/163US=84-A / Biol/Mol
Wilkinson DS, Barton MC. Transformig growth factor-B in developing and advanced cancers: tumor suppressors p53 and TGFB converge to regulate the alpha-fetoprotein oncodevelopmental tumor marker. In: Jakowlew SB. Transforming growth factor-beta in cancer therapy: cancer treatment and therapy. Amsterdam: Elsevier, 2008. p. 309-20. (Cancer Drug Discovery and Development) ISBN 978-1-58829-715-0.

P53; SMAD2; SMAD4; SNON; P73; CROMATINA; FIGADO; HEPATOMA


93/163US=84-A / Biol/Mol
Wilkinson DS, Barton MC. Transformig growth factor-B in developing and advanced cancers: tumor suppressors p53 and TGFB converge to regulate the alpha-fetoprotein oncodevelopmental tumor marker. In: Jakowlew SB. Transforming growth factor-beta in cancer therapy: cancer treatment and therapy. Amsterdam: Elsevier, 2008. p. 309-20. (Cancer Drug Discovery and Development) ISBN 978-1-58829-715-0.

P53; SMAD2; SMAD4; SNON; P73; CROMATINA; HEPATOMA


94/163US=86 / Biol/Mol
Kuribayashi K, El-Deiry W. Regulation of programmed cell death by the P53 pathway. In: Khosravi-Far R, White E. Programmed cell death in cancer progression and therapy. New York: Springer, 2008. p. 201-21. (Advances in Experimental Medicina and Biology, 615) ISBN 978-1-4020-6553-8.

REGULACAO DA MORTE CELULAR PROGRAMADA; VIA P53; APOPTOSE; TRANSCRICAO; RECEPTORES TRAIL; MORTE CELULAR DEPENDENTES DE P53


95/163US=111 / Câncer
Bourdon JC, Lane DP. p53 family pathway in cancer. In: Alison MR. The cancer handbook. 2nd ed. New Jersey: John Wiley & Sons, 2007. p. 272-81. ISBN 978-0-470-01852-1.

CANCER; FAMILIA P53; SINALIZACAO DA P53


96/163US=36 / Gastro
Kelly CR, Wands JR. Molecular biology of liver carcinogenesis and hepatitis. In: Blumgart LH. Surgery of the biliary tract, and pancreas. 4th ed. Philadelphia: Elsevier Saunders, 2007. p. 153-63. (v.1) ISBN 978-1-4160-3256-8.

BIOLOGIA MOLECULAR DE CARCINOGENESE DO FIGADO; BIOLOGIA MOLECULAR DE HEPATITE; VIRUS DA HEPATITE B; VIRUS DA HEPATITE C; P53 GENE SUPRESSOR DE TUMOR E AFLATOXINAS; TELOMERO ENCURTAMENTO; TRANSDUCAO DE VIAS DE SINALIZACAO


97/163US=46 / Câncer
La Thangue NB. Theoretical foundations of cancer chemotherapy. In: Meyers RA. Cancer: from mechanisms to therapeutic approaches. New Jersey: Wiley-Blackwell, 2007. p. 369-87. ISBN 978-3-527-31768-4.

CANCER; QUIMIOTERAPIA; DESENHO DE DROGAS; TERAPIA; P53; CICLO CELULAR; ANGIOGENESE; HSP90; ERB B; E2F


98/163US=49 / Câncer
Joerger AC, Fersht R. Structural biology of the tumor suppressor p53 and cancer-associated mutants. In: Woude GFV, Klein G. Advances in cancer research. Amsterdam: Elsevier, 2007. p. 1-23. ISBN 978-0-12-006697-1.

BIOLOGIA ESTRUTURAL DO GENE SUPRESSOR TUMORAL P53; GENE SUPRESSOR TUMORAL P53; MUTACAO DO CANCER


99/163US=49 / Câncer
Wilman KG. Restoration of wild-type p53 function in human tumors: strategies for efficient cancer therapy. In: Woude GFV, Klein G. Advances in cancer research. Amsterdam: Elsevier, 2007. p. 321-38. ISBN 978-0-12-006697-1.

FUNCAO DE P53; TUMORES HUMANOS DE TIPO SELVAGEM; TERAPIA DO CANCER EFICIENTE; REACCAO DE MUTACAO DO P53; VIRUS TERAPEUTICO


100/163US=77-J / Câncer
Ikemori RY, Saito RF. Alterações metabólicas envolvidas no desenvolvimento tumoral. In: Lopes A, Chammas R, Iyeyasu H. Oncologia para a graduação. 3ª ed. São Paulo: Lemar, 2013. p. 142-9. ISBN 8-5866523-7-0.

CANCER; DESENVOLVIMENTO TUMORAL; ALTERACOES METABOLICAS; GLICOLISE AEROBIA; EFEITO WARBURG; HIF-1; PI3K/AKT/MTOR; P53; MYC; LACTATO DESIDROGENASE; GLUTAMINA; BIOSSINTESE DE LIPIDEOS; FARMACOS


Primeira | Anterior | Próxima | Última